Results 51 to 60 of about 4,410 (137)

Graves’ disease and exophthalmos — a mask for meningioma

Endokrynologia Polska, 2021
Not required for Clinical Vignette.
Kamila Mitka, Grzegorz Sokołowski, Dorota Pach, Alicja Hubalewska-Dydejczyk   +3 more
doaj   +1 more source

Neural Network-Based Pipeline With High-Resolution Feature Enhancement and Low-Resolution Feature Preservation for Automated Treatment Decision of Graves’ Orbitopathy Patients

IEEE Access
Graves’ orbitopathy is an inflammatory disorder that causes changes in different structures close to the eye. Accurate and consistent diagnoses are essential to improve the quality of life for Graves’ orbitopathy patients.
Sanghyuck Lee, Mohd Asyraf Zulkifley, Jeong Kyu Lee, Jaesung Lee   +3 more
doaj   +1 more source

Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy

Thyroid Research, 2019
Background Treatment of moderate to severe Graves’ orbitopathy (GO) is based mainly on intravenous pulses of methylprednisolone. High doses of methylprednisolone can exert several adverse effects, some of which might be life-threatening. The objective of
Dorota Walasik-Szemplińska, Grzegorz Kamiński, Iwona Sudoł-Szopińska   +2 more
doaj   +1 more source

Thyroid associated orbitopathy

Indian Journal of Ophthalmology, 2012
Thyroid associated orbitopathy, also known as Graves′ orbitopathy, is typically a self-limiting autoimmune process associated with dysthyroid states.
Rajat Maheshwari, Ezekiel Weis
doaj   +1 more source

Graves Orbitopathy [PDF]

Journal of Osteopathic Medicine, 2020
Stefano, Natali, Paul, Shogan
openaire   +2 more sources

Clinical assessment of patients with Graves' orbitopathy [PDF]

Medicinski Glasnik Specijalne Bolnice za Bolesti Štitaste Žlezde i Bolesti Metabolizma "Zlatibor", 2011
Clinical examination is the basis of a good assessment of a patient with Graves' orbitopathy. This study gives recommendations of the European orbitopathy group related to the activity and severity of the disease. The activity of the disease is estimated
Nedeljković-Beleslin Biljana
doaj   +1 more source

Upper eyelid retraction disclosed after edrophonium chloride administration in a patient with Graves' orbitopathy and myasthenia gravis

Clinical Ophthalmology, 2012
Hyera Kang,1,2 Yasuhiro Takahashi,1 Masayoshi Iwaki,1 Shinichi Asamura,3 Hirohiko Kakizaki,11Department of Ophthalmology, Aichi Medical University, Nagakute, Aichi, Japan; 2Department of Ophthalmology, Presbyterian Medical Center, Jeonju, Korea ...
Kang H, Takahashi Y, Iwaki M, Asamura S, Kakizaki H   +4 more
doaj  

Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab

European Thyroid Journal
Introduction: Secondary thyroid autoimmunity, especially Graves’ disease (GD), frequently develops in patients with multiple sclerosis (MS) following alemtuzumab treatment (ALTZ; anti-CD52). Thyroid eye disease (TED) can also develop, and rituximab (RTX;
Ilaria Muller, Sara Maioli, Mirco Armenti, Laura Porcaro, Nicola Currò, Elisabetta Iofrida, Lorenzo Pignataro, Jacopo Manso, Caterina Mian, Jens Geginat, Mario Salvi   +10 more
doaj   +1 more source

Surgical Treatment of Graves’ Orbitopathy

, 2023
Abstract Surgical treatment for patients with Graves’ orbitopathy consists of orbital decompression, strabismus surgery and eyelid surgery. In this chapter, we will limit ourselves to orbital decompression (refer for strabismus surgery: Chap. 6 and for eyelid surgery: Chap.
Mourits, Maarten P., Gooris, Peter J. J., Bergsma, J. Eelco   +2 more
openaire   +2 more sources

Graves′ orbitopathy: Management of difficult cases

Indian Journal of Endocrinology and Metabolism, 2012
Management of Graves′ ophthalmopathy (GO) is based on three pillars: to stop smoking, to restore and maintain euthyroidism, and to treat the eye changes according to severity and activity of GO.
Wilmar M Wiersinga
doaj   +1 more source